For the past 18 months we have had a very productive relationship with the Dalton Medicinal Chemistry team
Boston, MA and Toronto, ON (PRWEB) October 29, 2009
BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry have jointly announced a renewal of their exclusive worldwide collaboration and agreement to discover and develop new ophthalmology therapeutics.
Dalton Medicinal Chemistry will continue to utilize their proprietary insights to advance several novel classes of compounds against selected BIKAM targets. BIKAM will advance these agents with their growing cutting edge battery of biological assays and delivery methodologies.
David Garvey, VP, Chemistry at BIKAM commented: “For the past 18 months we have had a very productive relationship with the Dalton Medicinal Chemistry team”.
Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: “It’s been exceptionally exciting to work with the talented scientists at BIKAM to advance these important programs towards clinical development and beyond. We are delighted to have the opportunity to further contribute to these pioneering programs.”
BIKAM, Inc. is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of degenerative eye diseases and disorders. BIKAM is building a portfolio of product candidates based on patented technologies that were identified at the University of Florida, Gainesville. BIKAM investors include HealthCare Ventures, CHL Medical Partners and Fidelity Biosciences.
About Dalton Medicinal Chemistry & Dalton Pharma Services
Dalton Medicinal Chemistry Incorporated (DMC) was established to offer select partners medicinal chemistry capabilities in design and synthesis of new chemical entities.
DMC focuses on quality, creativity and speed in the delivery of innovative, high quality medicinal chemistry capabilities for the identification of new chemical entities which advance our clients' drug discovery programs. Our contributions to clinical development candidate selection include SAR elucidation, design and synthesis of focused compound arrays, hit to lead, lead optimization and generation of intellectual property. DMC has full access to Dalton Pharma Services (DPS) and its world class synthetic laboratories equipped with the latest technology in modern synthetic chemistry, structural determination and purity assessment.
Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.
dgarvey (at) bikampharma (dot) com
Dalton Medicinal Chemistry